Deutsche Bank keeps EUR 295.00 target for UCB stock

Published on 10/16/2026 at 16:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Valuation stood at 17.66 times earnings on October 16, 2026. UCB stock costs EUR 204.10 on October 16, 2026, down 0.92 percent versus the Brussels close.

Analyst valuation and price position

Deutsche Bank kept a EUR 295.00 target for UCB on October 16, 2026.
UCB traded at a price-to-earnings ratio of 17.66 on October 16, 2026.
UCB stock costs EUR 204.10 at Lang & Schwarz on October 16, 2026 at 4:00 p.m. CEST, 0.92 percent below the Euronext Brussels close of October 15, 2026.
UCB had a market capitalization of EUR 38.9 billion on October 16, 2026.

Aquarellmalerei der Brüsseler Skyline mit historischen Türmen und modernen Bürotürmen bei Sonnenuntergang — UCB S.A., ISIN BE0003739530, dargestellt durch stimmungsvolles Aquarell der Brüsseler Skyline bei Sonnenuntergang, Illustration mit AI erstellt.

Deutsche Bank maintained a EUR 295.00 target for UCB stock on October 16, 2026, putting the target 44.54 percent above the EUR 204.10 Lang & Schwarz price at 4:00 p.m. CEST. The broker also kept a buy rating, according to MarketScreener. UCB stock was trading at EUR 204.10 at Lang & Schwarz on October 16, 2026 at 4:00 p.m. CEST, down 0.92 percent versus the Euronext Brussels close of October 15, 2026 at EUR 206.00.

Valuation stays at 17.66 times earnings

The valuation measure gives the analyst target a concrete market anchor. UCB had a price-to-earnings ratio of 17.66 and a market capitalization of EUR 38.9 billion on October 16, 2026. The target distance uses the same euro basis as the share price and places the broker's EUR 295.00 level 44.54 percent above the Lang & Schwarz quote.

Price sits above the yearly low

UCB's Euronext Brussels quote was EUR 204.00 at 3:47 p.m. CEST on October 16, 2026. The session range ran from EUR 201.30 to EUR 205.00, while volume reached 47,383 shares against an average volume of 239,458 shares. The 52-week range extended from EUR 197.45 to EUR 289.50, leaving the stock 3.37 percent above its low and 29.50 percent below its high.

Pipeline milestones extend into 2027

UCB's investor page lists topline results for STACCATO alprazolam in the fourth quarter of 2026 and further clinical milestones in the first half of 2027. The page also reports BIMZELX sales of EUR 1.52 billion in the first half of 2026 and more than 135,000 patients reached globally in that period, according to UCB. Those milestones give the valuation a forward operating backdrop without changing the dated price comparison.

Market context for UCB

UCB is listed on Euronext Brussels and belongs to the BEL 20. Its business spans neurological and immunological medicines, with biotechnology classified as its industry. The current price remains 3.37 percent above the 52-week low, while the analyst target stands 44.54 percent above the Lang & Schwarz quote.

Stock position after the afternoon quote

The share price stayed inside the October 16, 2026 intraday range and below its 52-week high. The further course of trading is shown by the continuously updated real-time quote of UCB stock.